Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2019 Results Conference Call August 15, 2019 4:30 PM ET

Company Participants

Neda Safarzadeh - Head, IR
Joseph Payne - President and CEO
Andy Sassine - CFO
Dr. Pad Chivukula - Chief Scientific Officer and COO

Conference Call Participants

Ed Arce - H.C. Wainwright
Kumar Raja - Brookline Capital
Wangzhi Li - Ladenburg Thalmann

Operator

Greetings and welcome to the Arcturus Therapeutics Holdings Second Quarter 2019 Earnings Results Conference Call. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.

I would now like to turn the conference over to your host, Neda Safarzadeh, Head of Investor Relations. Thank you. You may begin.

Neda Safarzadeh

Thank you, operator, and good afternoon, everyone. Thank you for joining Arcturus’ earnings conference call. We are excited for this opportunity to discuss Arcturus’ second quarter 2019 operating results.

We are joined today by Joseph Payne, our President and Chief Executive Officer; and Andy Sassine, our Chief Financial Officers. Dr. Pad Chivukula, our Chief Scientific and Chief Operating Officer is also on the line and will be available to address questions during the Q&A session.

Joe will kick off the call with a high level overview of Arcturus’ market opportunity and the strategic roadmap. He will then review the Company's most recent partnership announcements and review important milestones for our clinical development activities. Next, Andy will be discussing the second quarter financial results and recap recent developments towards strengthening the Company's balance sheet. Finally, we will open the call for your questions.

Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and any responses to questions on this conference call constitute